Solid-state characterization of buspirone hydrochloride polymorphs

Pharmaceutical Research

Volumn 23, Issue 5, 2006, Pages 1043-1050

  Sheikhzadeh, M ^a   Rohani, S ^a   Jutan, A ^a   Manifar, T ^a   Murthy, K ^b   Horne, S ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Apotex PharmaChem Inc   (Canada)

Author keywords

Buspirone hydrochloride; Characterization; Polymorphism

Indexed keywords

ANTI-ANXIETY AGENTS; BUSPIRONE; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLOGRAPHY, X-RAY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; TECHNOLOGY, PHARMACEUTICAL;

EID: 33646876184     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9779-6     Document Type: Article

References (9)

1. A. S. Raw M. S. Faurness D. S. Gill R. C. Adams F. O. Holcombe L. X. Yu 2004 Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs) Adv. Drug Delivery Rev. 56 397 414
2. R. J. Behme T. T. Kensler, and D. G. Mikolasek. U.S. Patent 4,810,789, 1989.
3. Z. Chilmonczyk J. Cybulski A. Szelejeweska A. Les 1996 NMR studies of buspirone analogues J. Mol. Struct. 358 195 207
4. D. S. Aldrich M. A. Smith 1995 Pharmaceutical Applications of Infrared Spectroscopy Marcel Dekker, Inc. New York 323 375
5. A. Burger R. Ramberger 1979 Mikrochim. Acta 2 259
6. A. Burger R. Ramberger 1979 Mikrochim. Acta 2 273
7. T. Vankeirsblick A. Vercauteren W. Baeyens 2002 Applications of Raman spectroscopy in pharmaceutical analysis J. Pharm. Sci. 89 1342 1353
8. H. G. Brittain (ed). Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York, 1999.
9. M. Mirmehrabi S. Rohani K. S. K. Murthy B. Radatus 2004 Solubility, dissolution rate and phase transition studies of ranitidine hydrochloride tautomeric forms Int. J. Pharm. 282 73 85